Datum Källa Rubrik Typ Alternativ
2024-06-04 OssDsign OssDsign AB: OssDsign publicerar Årsredovisning 2023 Pressreleaser Ladda ner | Visa Stäng
2024-06-04 OssDsign OssDsign AB: OssDsign publishes Annual Report 2023 Pressreleaser Ladda ner | Visa Stäng
2024-05-30 OssDsign OssDsign AB: 5,000 patients treated with OssDsign Catalyst® in the U.S. Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 30 May 2024 | OssDsign

OssDsign AB: 5,000 patients treated with OssDsign Catalyst® in the U.S.

The continuous and rapid increase in treated patients is a strong testament to how well OssDsign Catalyst has been received in the U.S. market since its launch in August 2021.

”With 5,000 patients treated, the use of OssDsign Catalyst is not just growing, it’s accelerating. This is a significant leap from the earlier announcements of 2,000 patients treated in September 2023 and 1,000 patients in May 2023, demonstrating the rapid pace with which we are building our orthobiologics business,” said Morten Henneveld, CEO of OssDsign.

OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue in the body. 12-month results from the clinical study TOP FUSION, published in the peer-reviewed journal Biomedical Journal of Scientific & Technical Research, show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with OssDsign Catalyst.

2024-05-30 OssDsign OssDsign AB: 5 000 patienter behandlade med OssDsign Catalyst® i USA Pressreleaser Ladda ner | Visa Stäng
2024-05-24 OssDsign OssDsign AB: NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN OSSDSIGN AB Pressreleaser Ladda ner | Visa Stäng
2024-05-24 OssDsign OssDsign AB: KALLELSE TILL ÅRSSTÄMMA I OSSDSIGN AB Pressreleaser Ladda ner | Visa Stäng
2024-05-16 OssDsign OssDsign AB: Change of financial calendar Pressreleaser Ladda ner | Visa Stäng
2024-05-16 OssDsign OssDsign AB: Ändring av finansiell kalender Pressreleaser Ladda ner | Visa Stäng
2024-05-15 Redeye Redeye: OssDsign Q1 - An accelerating turnaround Pressreleaser Ladda ner | Visa Stäng
2024-05-15 Carnegie Commissioned Research Carnegie Commissioned Research: OssDsign: A new beginning – Q1 review Pressreleaser Visa Stäng
2024-05-14 OssDsign OssDsign AB (publ) publishes Q1 2024 interim report Rapporter Ladda ner | Visa Stäng
2024-05-14 OssDsign OssDsign AB (publ) publicerar delårsrapport för första kvartalet 2024 Rapporter Ladda ner | Visa Stäng
2024-04-29 OssDsign OssDsign AB: OssDsign får tillgång till 100 nya sjukhus inom U.S. Veteran Affairs med sitt syntetiska bengraft Pressreleaser Ladda ner | Visa Stäng
2024-04-29 OssDsign OssDsign AB: OssDsign expands military access with new contract covering 100 additional VA orthopedic hospitals Pressreleaser Ladda ner | Visa Stäng
2024-04-11 Carnegie Commissioned Research Carnegie Commissioned Research: OssDsign: Another quarter of triple-digit Catalyst growth expected Pressreleaser Visa Stäng
2024-04-02 OssDsign OssDsign AB: OssDsign awarded long-term agreement with Premier, Inc. Pressreleaser Ladda ner | Visa Stäng
2024-04-02 OssDsign OssDsign AB: OssDsign tecknar flerårigt avtal med Premier, Inc. Pressreleaser Ladda ner | Visa Stäng
2024-03-07 Carnegie Commissioned Research Carnegie Commissioned Research: OssDsign: Update after HC seminar and news in the spinal fusion market Pressreleaser Visa Stäng
2024-02-29 OssDsign OssDsign AB: OssDsign utser Tom Buckland till Chief Technical Officer Pressreleaser Ladda ner | Visa Stäng
2024-02-29 OssDsign OssDsign AB: OssDsign appoints Tom Buckland as Chief Technical Officer Pressreleaser Ladda ner | Visa Stäng
2024-02-07 Redeye Redeye: Q4 - Sales will go up, and costs will go down Pressreleaser Ladda ner | Visa Stäng
2024-02-07 Carnegie Commissioned Research Carnegie Commissioned Research: OssDsign: Restructuring completed, focus on 2024 Pressreleaser Visa Stäng
2024-02-06 OssDsign OssDsign AB (publ) publishes year-end report 2023 Rapporter Ladda ner | Visa Stäng
2024-02-06 OssDsign OssDsign AB (publ) publicerar bokslutskommuniké 2023 Rapporter Ladda ner | Visa Stäng
2024-01-29 Carnegie Commissioned Research Carnegie Commissioned Research: OssDsign: Right time to fuse the spine Pressreleaser Visa Stäng
2024-01-24 OssDsign OssDsign AB: 12-month data from the clinical study of OssDsign Catalyst™ published in Biomedical Journal of Scientific & Technical Research Pressreleaser Ladda ner | Visa Stäng
2024-01-24 OssDsign OssDsign AB: Tolvmånadersdata från klinisk studie med OssDsign Catalyst™ publicerad i Biomedical Journal of Scientific & Technical Research Pressreleaser Ladda ner | Visa Stäng
2024-01-09 OssDsign OssDsign AB: OssDsign reports exceptional data from the clinical study TOP FUSION Pressreleaser Ladda ner | Visa Stäng
2024-01-09 OssDsign OssDsign AB: OssDsign rapporterar exceptionella data från den kliniska studien TOP FUSION Pressreleaser Ladda ner | Visa Stäng
2023-12-07 Redeye Redeye: OssDsign - Higher-than-expected Q4 preliminary sales Pressreleaser Ladda ner | Visa Stäng
2023-12-06 OssDsign OssDsign AB: OssDsign's revenues for the fourth quarter of 2023 are expected to exceed market estimates Pressreleaser Ladda ner | Visa Stäng
2023-12-06 OssDsign OssDsign AB: OssDsigns intäkter för det fjärde kvartalet 2023 förväntas överstiga marknadens förväntningar Pressreleaser Ladda ner | Visa Stäng
2023-11-30 OssDsign OssDsign AB: SEB Venture Capital has sold its holding in OssDsign Pressreleaser Ladda ner | Visa Stäng
2023-11-30 OssDsign OssDsign AB: SEB Venture Capital har avyttrat sitt innehav i OssDsign Pressreleaser Ladda ner | Visa Stäng
2023-11-30 OssDsign OssDsign AB: OssDsign byter Certified Adviser till Carnegie Investment Bank AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-11-30 OssDsign OssDsign AB: OssDsign changes Certified Adviser to Carnegie Investment Bank AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-11-23 Penser Access Penser Access: Intervju med OssDsign - Erik Penser Bank - 23 november 2023 Pressreleaser Visa Stäng
2023-11-22 Penser Access Penser Access: Benhård tillväxt - OssDsign Pressreleaser Visa Stäng
2023-11-22 Redeye Redeye: OssDsign Q3 - Catalyst is growing as expected Pressreleaser Ladda ner | Visa Stäng
2023-11-21 OssDsign OssDsign AB (publ) publicerar delårsrapport för tredje kvartalet 2023 Rapporter Ladda ner | Visa Stäng
2023-11-21 OssDsign OssDsign AB (publ) publishes Q3 2023 Interim Report Rapporter Ladda ner | Visa Stäng
2023-10-16 OssDsign Extra bolagsstämma har hållits i OssDsign AB Pressreleaser Ladda ner | Visa Stäng
2023-10-16 OssDsign Extraordinary General Meeting held in OssDsign AB Pressreleaser Ladda ner | Visa Stäng
2023-10-11 OssDsign OssDsign AB: OssDsign Catalyst blir allmänt tillgänglig för alla militära vårdinrättningar i USA via ECAT Pressreleaser Ladda ner | Visa Stäng
2023-10-09 Penser Access Penser Access: Intervju med OssDsign - Erik Penser Bank - 9 oktober 2023 Pressreleaser Visa Stäng
2023-09-28 Redeye Redeye: OssDsign - Fully funded and fully focused Pressreleaser Ladda ner | Visa Stäng
2023-09-28 Penser Access Penser Access: Strategiskifte och nyemission - OssDsign Pressreleaser Visa Stäng
2023-09-27 OssDsign Notice to attend the extraordinary general meeting in OssDsign AB Pressreleaser Ladda ner | Visa Stäng
2023-09-27 OssDsign Kallelse till extra bolagsstämma i OssDsign AB Pressreleaser Ladda ner | Visa Stäng
2023-09-26 OssDsign OssDsign AB: OssDsign has carried out a directed share issue of approximately SEK 150 million Rapporter Ladda ner | Visa Stäng
2023-09-26 OssDsign OssDsign AB: OssDsign har genomfört en riktad nyemission av aktier om cirka 150 miljoner kronor Rapporter Ladda ner | Visa Stäng
2023-09-26 OssDsign OssDsign AB: OssDsign explores the conditions to carry out a directed share issue Rapporter Ladda ner | Visa Stäng
2023-09-26 OssDsign OssDsign AB: OssDsign utreder förutsättningarna att genomföra en riktad nyemission av aktier Rapporter Ladda ner | Visa Stäng
2023-09-26 OssDsign OssDsign AB: OssDsign announces strategic shift to become a pure play orthobiologics company Rapporter Ladda ner | Visa Stäng
2023-09-26 OssDsign OssDsign AB: OssDsign genomför strategiskifte för att bli ett renodlat ortobiologiföretag Rapporter Ladda ner | Visa Stäng
2023-09-18 OssDsign OssDsign AB: OssDsign® Catalyst får utökat marknadsgodkännande från FDA för betydande ny indikation för användning i ryggradsburar Pressreleaser Ladda ner | Visa Stäng
2023-09-13 OssDsign OssDsign AB: 2 000 patienter behandlade med OssDsign[®] Catalyst i USA Pressreleaser Ladda ner | Visa Stäng
2023-08-30 Penser Access Penser Access: Intervju med OssDsign - Erik Penser Bank - 29 augusti 2023 Pressreleaser Visa Stäng
2023-08-24 Redeye Redeye: OssDsign - Catalyst sets up for a turnaround Pressreleaser Ladda ner | Visa Stäng
2023-08-23 Penser Access Penser Access: 148% tillväxt i USA - OssDsign Pressreleaser Visa Stäng
2023-08-22 OssDsign OssDsign AB (publ) publicerar delårsrapport för andra kvartalet 2023 Rapporter Ladda ner | Visa Stäng
2023-08-22 OssDsign OssDsign AB (publ) publishes Q2 2023 Interim Report Rapporter Ladda ner | Visa Stäng
2023-08-16 OssDsign OssDsign AB: OssDsign har passerat 200 patienter i sitt prospektiva multicenterregister för ryggradsfusion, PROPEL Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

5 Nov 2024 | Kvartalsrapport 2024-Q3